Defining a robust disease severity phenotype for use in genetic association studies

VG Jokubaitis; T Kalincik; D Horakova; E Havrdova; P Kleinova; K Kucerova; G Izquierdo; F Matesanz; A Lugaresi; TJ Kilpatrick; J Lechner-Scott; M Slee; M Barnett; S Vucic; D Booth; A Manouchehrinia; B Taylor; J Hillert; P de Jager; H Butzkueven

Conference Proceedings

Defining a robust disease severity phenotype for use in genetic association studies

VG Jokubaitis, T Kalincik, D Horakova, E Havrdova, P Kleinova, K Kucerova, G Izquierdo, F Matesanz, A Lugaresi, TJ Kilpatrick, J Lechner-Scott, M Slee, M Barnett, S Vucic, D Booth, A Manouchehrinia, B Taylor, J Hillert, P de Jager, H Butzkueven

MULTIPLE SCLEROSIS JOURNAL | SAGE PUBLICATIONS LTD | Published : 2016

University of Melbourne Researchers

Tomas Kalincik Author Medicine - Royal Melbourne Hospital

Trevor Kilpatrick Author Medicine, Dentistry and Health Sciences

Related Projects (1)

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

Grants

Awarded by Royal Melbourne Hospital

Awarded by CharityWorks for MS/MS Research Australia

Awarded by NHMRC Centre for Research Excellence Grant

Funding Acknowledgements

This study is supported by grants from The Royal Melbourne Hospital [MH2013-055]; The MSBase Foundation; CharityWorks for MS/MS Research Australia [MSRA12-062], and an NHMRC Centre for Research Excellence Grant [Grant ID 1001216]. The MSBase Foundation is an independent not for profit organisation which receives support in the form of grants from the National Health and Medical Research Council (NHMRC) Australia, Merck, Merck Serono, Biogen, Novartis, and Genzyme a Sanofi company.

Keywords

Neurosciences

Science & Technology

Life Sciences & Biomedicine

Neurosciences & Neurology

Clinical Neurology